Drugs / CLIC-2201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06208735 | Jan 2025 → Aug 2026 overdue | B-cell acute lymphoblastic leukemia, high grade B-cell lymphoma, mantle cell lymphoma, primary mediastinal large B-cell lymphoma | British Columbia Cancer Agency | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CLIC-2201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06208735 ↗ |
| Modality | Cell therapy | “This is a Phase I, first-in-human, open-label multicenter trial of CLIC-2201 CAR-T cells for participants with relapsed/refractory B cell malignancies.” NCT06208735 ↗ |
| Route | Intravenous | “A single Intravenous infusion of CLIC-2201 will be given.” NCT06208735 ↗ |
| Target | CD22 | “CD22 targeting chimeric antigen receptor (CAR)-T cell product” NCT06208735 ↗ |